Prevalence of non-Hodgkin lymphomas in São Paulo, Brazil

Gouveia, Gisele Rodrigues; Siqueira, Sheila Aparecida Coelho; Chamone, Dalton de Alencar Fischer; Pereira, Juliana

doi:10.5581/1516-8484.20110085

Cited by 10 publications

(14 citation statements)

References 3 publications

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Geographic differences may influence the immunophenotype of lymphomas in man, which can be extrapolated to dogs (Fournel-Fleury et al 2002). However, in the State of São Paulo, in a study of the immunophenotypes of lymphomas in humans, a predominance of B-cell lymphoma was found (Gouveia et al 2011), whereas in a study in dogs, also in São Paulo, T-cell lymphoma was predominant. Ponce et al (2010) observed 35.4% of T-cell lymphomas in dogs and suggested that this percentage may be related to the greater number of skin biopsies performed, all with a T-cell immunophenotype.…”

Section: Discussionmentioning

confidence: 99%

Canine lymphomas diagnosed in southern Brazil from 2000 to 2017: epidemiology and immunophenotype

et al. 2019

View full text Add to dashboard Cite

Lymphoma is a neoplasm that originates from solid hematopoietic tissues and is one of the most common tumors in dogs. The goal of the present study was to perform a retrospective study of canine lymphomas diagnosed at the “Laboratório Regional de Diagnóstico”, at the “Faculdade de Veterinária” of the “Universidade Federal de Pelotas” (LRD-UFPel) from 2000 to 2017, to determine the epidemiology and anatomical distribution, and to evaluate the histopathological and immunohistochemical aspects of each case according to the adapted Kiel classification. The protocols for necropsies and biopsies in the laboratory were reviewed. Lymphoma was diagnosed in 77 dogs. Approximately 37.7% (29/77) of affected dogs had no defined breed, while dogs with defined breeds accounted for 58.4% (45/77) of the diagnoses. The occurrence in males (40/77) was slightly higher than that in females (36/77), and the mean age was 8.1 years (1.4-17 years). The most affected age group was between six and 10 years of age with 31 cases (40.2%). Regarding the anatomical classification, the multicentric form was the most prevalent, accounting for 71.4% (55/77) of the diagnoses. In 40 cases that immunophenotyping was performed, B-cell lymphomas represented 62.5% of the diagnoses (25/40), while T-cell lymphomas corresponded to 37.5% of the diagnoses (15/40). The degree of malignancy according to the modified Kiel classification was low in 35% of lymphomas (14/40) and high in 65% of cases (26/40). The multicentric form was more frequent in the region of influence of the LRD-UFPel. Identification of the immunophenotype can improve the quality of life and survival in affected dogs since it allows the most appropriate treatment for each patient.

show abstract

Section: Discussionmentioning

confidence: 99%

Canine lymphomas diagnosed in southern Brazil from 2000 to 2017: epidemiology and immunophenotype

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The frequencies of the MBCN subtypes found in this study are similar to those described in international and Brazilian studies. 11 , 12 …”

Section: Discussionmentioning

confidence: 99%

Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil

Cardoso

Moraes

Moral

et al. 2016

Revista Brasileira de Hematologia e Hemoterapia

View full text Add to dashboard Cite

BackgroundAccording to the 2008 World Health Organization classification, mature B-cell neoplasms are a heterogeneous group of diseases that include B-cell lymphomas and plasma cell disorders. These neoplasms can have very different clinical behaviors, from highly aggressive to indolent, and therefore require diverse treatment strategies.ObjectiveThe aim of this study was to assess the profile of 93 patients diagnosed with mature B-cell neoplasms monitored between 2011 and 2014.MethodsA review of patients’ charts was performed and laboratory results were obtained using the online system of the Universidade Federal de Santa Catarina.ResultsThe study included 93 adult patients with mature B-cell neoplasms. The most frequent subtypes were multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. The median age at diagnosis was 58 years with a male-to-female ratio of 1.3:1. There were statistical differences in terms of age at diagnosis, lactate dehydrogenase activity and Ki-67 expression among the subtypes of B-cell lymphoma. According to the prognostic indexes, the majority of multiple myeloma patients were categorized as high risk, while the majority of chronic lymphocytic leukemia patients were classified as low risk.ConclusionsThis study demonstrates the profile of patients diagnosed with mature B-cell neoplasms in a south Brazilian university hospital. Of the B-cell lymphoma, Burkitt's lymphoma presented particular features regarding lactate dehydrogenase activity levels, Ki-67 expression, age at diagnosis, and human immunodeficiency virus infection.

show abstract

“…DLBCL represents 80% of all aggressive lymphomas (3) and 30 to 40% of all NHL cases in the West and are one of the most frequent in developing countries (2) . At the Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo -HCFMUSP, DLBCL represents 49.57% of all NHL cases (9) . NHL is the fifth most common type of cancer in Brazil, with an incidence of 55,000 cases and over 26,000 deaths per year (10) .…”

Section: Epidemiologymentioning

confidence: 99%

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Gouveia¹,

Siqueira²,

Pereira³

2012

Revista Brasileira De Hematologia E Hemoterapia

Self Cite

View full text Add to dashboard Cite

Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo -HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multifactorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6, and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.

show abstract

Prevalence of non-Hodgkin lymphomas in São Paulo, Brazil

Cited by 10 publications

References 3 publications

Canine lymphomas diagnosed in southern Brazil from 2000 to 2017: epidemiology and immunophenotype

Canine lymphomas diagnosed in southern Brazil from 2000 to 2017: epidemiology and immunophenotype

Mature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern Brazil

Pathophysiology and molecular aspects of diffuse large B-cell lymphoma

Contact Info

Product

Resources

About